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Abstract Standard clinical protocols and the concept “one 
drug fits all” that are currently used to treat illness in many 
cases are not effective, and strikingly so in the treatment 
of cancer, where 75% of therapeutic schemes are inef-
fective. The concept of personalized medicine is that the 
treatment of the disease is designed on the basis of the 
individual needs of each patient and the factors that in-
fluence their response to different drugs. Individualization 
of patient care has the potential to generate novel effec-
tive therapies, limit the adverse drug effects, create optimal 
treatments for individual patients, and decrease the cost 
associated with chronic illness and complications of drug 
usage. However, to achieve the goals of personalized med-
icine many challenges must be addressed. Here we discuss 
possible ways to increase the consistency of data generat-
ed by basic research and their suitability for application in 
medicine. New technologies employing systems biology 
and computer based approaches will facilitate overcoming 
many of the scientific challenges in the field. Changes in 
the education of researchers, health professionals, and the 
public are also required to successfully implement person-
alized medicine as a routine in the clinic. Finally, shift of the 
focus away from the development of blockbuster drugs in 
the biopharmaceutical industry, and modifications in the 
legal system to accommodate novel advancements need 
to be considered. The joint effort of all interested parties is 
needed to generate an efficient roadmap that will take us 
rapidly and safely to effective individual treatment, which 
will eliminate diseases and create better health care for all.
PERSONALIZED MEDICINE: BACKGROUND AND 
SIGNIFICANCE
The European Cooperation in Science and Technology 
(COST) Conference entitled “Personalised Medicine: 
Better Healthcare for the Future” held in June 2012, in Lar-
naca, Cyprus focused on identifying ways of improving pa-
tient care and outlining the required measures to further 
develop medical, science, and technology fields in order to 
provide better medicine for all (1). The diversity of the dis-
ciplines of the delegates which included biologists, math-
ematicians, engineers, computer scientists, chemists, clini-
cians, sociologists, philosophers as well as politicians, and 
representatives from funding agencies and pharmaceuti-
cal companies reflected the different angles from which 
the subject of personalized medicine was viewed.
Personalized medicine is defined as the individualized 
treatment tailored to the needs of a particular patient 
and not based only on the type of their illness. The aim 
of personalized medicine is to design appropriate treat-
ment for each person’s unique needs, taking into account 
clinical, biological, genetic, environmental, and socioeco-
nomic factors and life styles. This ideally should allow ac-
curate predictions to be reached about a person’s sus-
ceptibility to develop disease, response to treatment, and 
elimination of therapeutic failure and toxicity. Currently, 
many diseases are not treated successfully, the therapeu-
tic strategies are often symptomatic, and numerous drugs 
are effective only for certain groups of patients (2). The ef-
fective dose of the appropriate medicine prescribed for a 
particular disease might vary among different individuals 
depending on the patient genetic constitution. Further-
more, the choice of the medicine and the effective dose 
might be different for the same individual at different 
stages of their life. Although selective toxicity has been 
known for several years it has recently become evident 
that this is mostly attributable to the action of metaboliz-
ing enzymes such as members of the cytochrome P450 
family, which alter drug metabolism and can affect phar-
macodynamic parameters depending on the genetic 
background of the patient (3).
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A few examples of stratified therapies used in the clini-
cal practice include the case of non-small cell lung can-
cer (NSCLC), in which either the epidermal growth factor 
receptor (EGFR) (4) or the anaplastic lymphoma kinase 
(ALK) pathways are deregulated (5). Cancer patients car-
rying mutations in the EGFR pathway respond better to 
Tarceva (erlotinib), whereas the recently approved che-
motherapeutic drug Xalkori (crizotinib) is more efficient 
in those patients bearing (ALK) gene rearrangement (6). 
Breast cancer patients overexpressing human epidermal 
growth factor receptor 2 (HER2) are treated with the an-
tibody Herceptin (trastuzumab), which inhibits this path-
way providing another promising paradigm of personal-
ized treatment (7). Patient stratification is also employed 
for treatment of coagulation disorders with warfarin based 
on CYP2C9, vitamin K epoxide reductase complex, subunit 
1 (VKORC1) and Protein C status, and international normal-
ized ratio values determined throughout the period of the 
treatment (8). The treatment of metastatic melanoma with 
the BRAF inhibitor is dependent on the status of this ki-
nase in the tumor (9). Although a few prominent cases of 
personalized medicine have recently emerged, we are still 
far from efficiently treating many diseases as complications 
due to the side effects of drugs, and the increasing costs of 
the therapeutic failure remain considerable.
CHALLENGES ENCOUNTERED IN THE FIELD OF 
PERSONALIZED MEDICINE
Analysis of the efficacy of numerous drugs currently used 
to treat major diseases shows that many patients do not 
respond to therapy. This could vary from 20% treated with 
analgesics up to 75% of cancer patients treated with che-
motherapeutics (10), indicating that we are still far from 
knowing which genetic markers have the most clinical sig-
nificance in various diseases and different individuals (11). 
One potential reason for the inefficiency of several thera-
peutic schemes is that the experimental settings currently 
used for biotechnology-oriented research and drug devel-
opment processes may not be translated efficiently into 
the clinical practice. Possible ways to address this problem 
is to increase investment in bridging basic and translational 
research and foster collaborative multidisciplinary studies 
(12). Furthermore, information about both basic and trans-
lational research should become readily available. For ex-
ample, to improve the consistency of published data, neg-
ative results that do not confirm hypothesis and data sets 
without the completed molecular mechanisms involved, 
should become acceptable for publication in high impact 
and open access journals linked to as many databases as 
possible. The increase of data availability will provide wid-
er base for data mining, improve the modeling of diseases 
and therapeutic schemes, and shorten the time and cost 
of the drug development and clinical trials processes (13).
In addition to individual variability, many diseases are het-
erogeneous in terms of the underlying cause. For exam-
ple, one or more of the hallmarks of cancer (14) can vary 
between individual tumors and arise due to oncogene 
activation or mutations of tumor suppressor genes, and 
their combined effects on each pathway might be selec-
tively changed in a particular cell type within the tumor 
and hence require different pharmacological interven-
tion. Treatment of heterogeneous populations of tumor 
cells with the same drug, in most cases leads to resistance, 
therefore continuous assessment of the evolution of the 
disease at the molecular level is necessary to address these 
issues. Generation of large logical models that incorporate 
many interactions facilitates the identification of potential 
shifts in the dependency of cancer cells from one particu-
lar signaling pathway to another during a course of treat-
ment, thereby allowing design of alternative therapeutic 
protocols to avoid resistance. Finally, the stage of disease 
may determine the appropriate treatment as for example 
the levels of the CYP2E1 biomarker are high in early stages 
of breast cancer and gradually decline in later stages of tu-
mor development (15,16), therefore stratifying patients ac-
cording to the CYP2E1 cellular levels.
The vast amount of information that has accumulated 
throughout recent years of basic and clinical research has 
made it difficult to analyze the data collected so far using 
current methodologies. Novel systems biology and text 
mining approaches coupled with bioinformatics and in-
novative modeling techniques are of crucial importance 
for progress in the field. The assembly of a multidisciplinary 
team including biologists, physicists, and clinicians was the 
only way to successfully address complicated issues we 
encountered in some of our studies (17,18).
It has become clear that successful implementation of per-
sonalized treatment requires changes in the education of 
future clinicians, health professionals, and basic scientists 
to include fundamental elements of pharmacogenetics 
and pharmacogenomics. In addition, confidence in the 
efficiency of individualized medicines will increase if in-
formation about advancements in the field is conveyed 
to the patients and the public. Novel pilot schemes and 
training programs for health professionals are in devel-
opment in France (19). It will be necessary to expand 
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these types of educational programs that include systems 
and synthetic biology and predictive modeling approach-
es in order to prepare health professionals and other mem-
bers of future interdisciplinary teams for participation in 
collaborative research projects and management of per-
sonalized therapies. More has to be done toward refining 
the legal frame regarding privacy issues that individual 
treatment may bring. Who will be allowed to have access 
to sensitive patients’ data? How access to these data could 
be restricted to those professionals whose primary inter-
est is the benefit to the patients’ health? It is essential that 
potential adverse influence of this information on employ-
ability, life and health insurance policies, and other areas of 
everyday life is prevented. Opportunities must be explored 
for more extensive public input and confidence in the no-
tion that the routine use of personalized medicine will lead 
to real health improvements.
Multidisciplinary and collaborative research is the way for-
ward to overcome barriers we all encounter in our research 
efforts due to lack of communication or understanding 
that is required to cross the boundaries into different dis-
ciplines. Successful collaborations usually emerge as a re-
sult of personality compatibilities between collaborators 
and not overlap in their scientific expertise, thus they are 
often left to chance. This is not sufficient to fulfill the ex-
pectations of innovative research in the future as multi-
disciplinary teams and collaborative efforts are essential 
prerequisites for success toward realizing the goals of per-
sonalized medicine. Therefore, we propose that we place 
in action mechanisms to facilitate collaboration and multi-
disciplinary approaches such as awarding researchers and 
clinicians with promotions and further research funds to 
encourage these efforts. COST has already fostered many 
of these successful events that facilitated collaborative ef-
forts and multidisciplinary approaches but more needs to 
be done toward these goals to involve other funding bod-
ies and institutions (20). For example, majority of cases for 
promotions at Universities, research institutions, and hos-
pitals are judged on individual’s own contribution to sci-
entific progress as an independent researcher, whereas 
collaborative efforts are mostly viewed as lower impact 
contribution.
Finally, the question whether personalized medicine will be 
cost-effective and how it will be funded has not yet been 
clearly answered. Why do we need basic, curiosity driven, 
“blue sky” research and especially now in a period of fi-
nancial crisis? How can funding of something the pub-
lic does not understand be of benefit? Should we 
fund only applied research? The wider population should 
become aware of the benefits of funding basic research 
and multidisciplinary approaches as progress in science is 
the only way forward.
CONCLUSIONS AND PERSPECTIvES
Diagnosis and treatment of illness are currently performed 
on the basis of clinical protocols designed for a particular 
disease and not a particular patient. However, given the 
low efficacy of numerous drugs, the high cost of their de-
velopment, and the price national health systems pay for 
the management of chronic patients and complications of 
drug treatments, the urgent need to shift the focus from 
designing one drug that fits all toward the research that 
actively pursues the goals of personalized medicine is be-
coming apparent.
Taking this path has many challenges and complexities. The 
way that knowledge accumulated through basic science 
research is transferred to drug development companies 
and general public must change to involve more transpar-
ent publication processes and include reporting negative 
data. Changes in researchers’ career progression and the 
way their work is judged need to be considered. Novel 
technologies addressing the heterogeneity of responses to 
drugs not only among different individual patients but in 
one patient affecting the response to treatment should be 
embraced. Technological advances in sequencing resulted 
in accumulation of vast data sets that need to be analyzed 
by novel mining tools and require changes in education 
of researchers and health professionals, as well as chang-
es in guidelines and legislation provided by the regulatory 
authorities. Finally, funding strategies seem to shift toward 
interdisciplinary teams but we must keep basic research 
funding strategies as well as providing ways of successfully 
fostering collaboration.
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